INT139069

From wiki-pain
Jump to: navigation, search
Context Info
Confidence 0.16
First Reported 2007
Last Reported 2008
Negated 0
Speculated 0
Reported most in Abstract
Documents 3
Total Number 3
Disease Relevance 0.65
Pain Relevance 0.70

This is a graph with borders and nodes. Maybe there is an Imagemap used so the nodes may be linking to some Pages.

plasma membrane (CTLA4, Cd86) Golgi apparatus (CTLA4)
Anatomy Link Frequency
CD86 3
CTLA4 (Homo sapiens)
Cd86 (Mus musculus)
Pain Link Frequency Relevance Heat
abatacept 7 99.96 Very High Very High Very High
rheumatoid arthritis 13 97.28 Very High Very High Very High
cytokine 14 86.56 High High
Inflammation 21 5.00 Very Low Very Low Very Low
Arthritis 18 5.00 Very Low Very Low Very Low
tolerance 8 5.00 Very Low Very Low Very Low
chemokine 5 5.00 Very Low Very Low Very Low
methotrexate 3 5.00 Very Low Very Low Very Low
corticosteroid 2 5.00 Very Low Very Low Very Low
Multiple sclerosis 1 5.00 Very Low Very Low Very Low
Disease Link Frequency Relevance Heat
Rheumatoid Arthritis 13 97.28 Very High Very High Very High
Autoimmune Disease 19 75.00 Quite High
General Immunology 2 69.60 Quite High
Rheumatic Diseases 12 50.00 Quite Low
Malignant Neoplastic Disease 1 42.64 Quite Low
INFLAMMATION 21 5.00 Very Low Very Low Very Low
Disease 18 5.00 Very Low Very Low Very Low
Juvenile Chronic Polyarthritis 16 5.00 Very Low Very Low Very Low
Systemic Lupus Erythematosus 13 5.00 Very Low Very Low Very Low
Graft Vs Host Disease 4 5.00 Very Low Very Low Very Low

Sentences Mentioned In

Key: Protein Mutation Event Anatomy Negation Speculation Pain term Disease term
Preferential engagement of CTLA-4, instead of CD28, with CD80/CD86 may provide a negative proliferative signal [78].
CTLA-4 Binding (engagement) of CD86 in CD86
1) Confidence 0.16 Published 2008 Journal Pediatr Rheumatol Online J Section Body Doc Link PMC2633304 Disease Relevance 0 Pain Relevance 0.04
The selective costimulation modulator abatacept (CTLA-4Ig) binds to CD80 and CD86, blocking interaction with CD28, and is approved for the treatment of moderate to severe rheumatoid arthritis.
CTLA-4Ig Binding (binds) of CD86 in CD86 associated with rheumatoid arthritis and abatacept
2) Confidence 0.00 Published 2007 Journal Annu. Rev. Med. Section Abstract Doc Link 17020493 Disease Relevance 0.33 Pain Relevance 0.33
The selective costimulation modulator abatacept (CTLA-4Ig) binds to CD80 and CD86, blocking interaction with CD28, and is approved for the treatment of moderate to severe rheumatoid arthritis.
CTLA-4Ig Binding (interaction) of CD86 in CD86 associated with rheumatoid arthritis and abatacept
3) Confidence 0.00 Published 2007 Journal Annu. Rev. Med. Section Abstract Doc Link 17020493 Disease Relevance 0.33 Pain Relevance 0.33

General Comments

This test has worked.

Personal tools
Namespaces

Variants
Actions
Navigation
Toolbox